CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bioadaptives Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bioadaptives Inc
2620 Regatta Drive, Suite 102
Phone: (702) 659-8829p:702 659-8829 LAS VEGAS, NV  89128  United States Ticker: BDPTBDPT
On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.
Business Summary
BioAdaptives, Inc. operates in the health and wellness industry. The Company’s core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products in development include a weight management supplement in a human clinical trial, Zeranovia. Zeranovia is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. Xcellara regenerative stem cell activator is in production. Xcellara is its regenerative wellness solution, to enhance performance, accelerate recovery, and revitalize health. PawPa Regen is the canine treat stem cell activator. PawPa Regen supports anti-aging and wellness. Its other products include MyndMed and Wynovia. MyndMed is designed to optimize multiple neurotransmitter systems and neuroprotective pathways.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes---

Industries
SIC Code Description
5499 Miscellaneous food stores

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer JamesKeener 5/20/2024 5/20/2024
Director Gimhana S.Dissanayake 5/30/2024 5/30/2024
Director MarkFrissora 2/3/2025 2/3/2025

Business Names
Business Name
APEX 8 Inc.,
BDPT
BDPTD
Blender’s Choice Inc.

General Information
Number of Employees: 1 (As of 3/31/2025)
Outstanding Shares: 9,048,659 (As of 5/2/2025)
Shareholders: 135
Stock Exchange: OTC
Federal Tax Id: 462592228
Fax Number: (302) 645-1280


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, July 14, 2025